The Effect Observation of Lianhua Qingwen Granule in the Adjuvant Treatment of Community Acquired Pneumonia (CAP)

Objective To observe the efficacy of Lianhua Qingwen Granule in the adjuvant treatment of community-acquired pneumonia (CAP). Methods From March 2018 to January 2020, adult patients with CAP who visited the internal medicine clinic of community health service center of Minzu University of China were divided by a random code list into two groups: the observation group (31cases), Lianhua Qingwen Granule orally combined with Levofloxacin intravenous drop, The control group (31 cases), Levofloxacin intravenous drop alonely. The cough symptom score, the cough visual simulation score (VAS), antipyretic time and X-ray chest shadow absorption were compared between the two groups to judge the curative effect. Measurement data were expressed as mean±standard deviation, and comparison used independent sample t test. Enumeration data were expressed as percentages, total effective rates were compared by χ2 tests. Results There were no statistically significant differences in baseline data, such as age, score of cough symptom before treatment between the two groups. Compared with the control group, cough symptom score and VAS of observation group decreased significantly [(2.45±1.312) point vs (3.61±1.476) point, P=0.002], [(3.68±1.973) point vs (4.84±1.753) point, P=0.017], antipyretic time was decreased significantly [(3.00 ±1.4814) day VS (4.842±1.5728) day, P=0.001], effective rate was increased significantly (87.1% VS 64.5%, P=0.038). Compliance: the rate of hospital transfer without medical advice was decreased significantly (6.45% VS 29.03% P=0.046). Conclusion Lianhua Qingwen Granule combined with levofloxacin has good efficacy and compliance in the treatment of CAP, and community doctors can choose it.